CMBA
DNLI icon

C.M. Bidwell & Associates’s Denali Therapeutics DNLI Stock Holding History

C.M. Bidwell & Associates’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-250
Closed -$21K – 520
2020
Q4 		$21K Sell
250
-170
-40% -$10.3K 0.02% 334
2020
Q3 		$15K Buy
+420
New +$12.6K 0.01% 318

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

C.M. Bidwell & Associates's DNLI Position: Q1 2021 in Review

C.M. Bidwell & Associates sold out of Denali Therapeutics (DNLI) in Q1 2021, closing a stake of 250 shares — an estimated $21K sold.

C.M. Bidwell & Associates first reported a position in DNLI in Q3 2020 and held it in 2 quarters. The position peaked at $21K in Q4 2020. 216 funds tracked by Wall St. Rank hold DNLI as of Q1 2021.

  • C.M. Bidwell & Associates reported no remaining Denali Therapeutics position as of Q1 2021 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 250 Denali Therapeutics shares in Q1 2021, an estimated $21K.
  • C.M. Bidwell & Associates first reported a position in Denali Therapeutics in Q3 2020 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Denali Therapeutics position peaked at $21K in Q4 2020.
  • 216 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2021, filed 14 May 2021.